Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc is advancing its pipeline candidates in high-value indications, notably highlighting the potential impact of SER-270 and its implications for long-term forecasts. The company's valuation assessment currently does not account for contributions from SER-270 or other pipeline candidates beyond SER-252, suggesting that successful clinical developments in these areas could significantly enhance the company's financial outlook. Additionally, the broadening approval trajectory of enFuse is anticipated to positively influence the global acceptance of SER-252, further solidifying the investment case for Serina Therapeutics.

Bears say

Serina Therapeutics has reported a consistent net loss of $0.64 per share, highlighting ongoing financial challenges that may reflect deeper operational issues within the company. The company faces multiple risks that could hinder the advancement of its lead candidate, SER-252, including delays in clinical assessment, difficulties in securing regulatory approvals, and slower-than-anticipated commercial uptake due to increased competition and market dynamics. Furthermore, revised forecasts indicate a significant increase in projected net losses, with estimates for 2025 rising dramatically to a loss of $2.01 per share, suggesting concerns over financial sustainability and future performance.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.